Skip to main content

Table 2 Extracellular vesicle (EV) treatment for preclinical studies in disease models

From: Engineering strategies for customizing extracellular vesicle uptake in a therapeutic context

Disease models

In vivo/in vitro

Administration route

Delivery (sustained release/injection)

Engineered/non-engineered

Methods for Enhancing EVs therapeutic effects

References

Chronic liver failure

In vivo

Systemic

Sustained release

Hydrogel-mediated

–

[62]

Alzheimer’s disease

In vivo

Systemic

Injection

Targeted

Engineering the dendritic cells to express Lamp2b fused to the neuron-specific RVG peptide for delivering exogenous siRNA

[43]

Breast cancer

In vitro

–

–

Engineered-targeted

HEK293T cells transduced by a lentiviral vector bearing-LAMP2b-DARPin G3 chimeric gene for siRNA delivering

[88]

Parkinson’s disease

In vivo/ in vitro

Systemic

–

Engineered

Catalase loading into exosomes by different methods

[125]

Cartilage damage

In vivo/in vitro

Local

Injection

–

–

[5]

Osteoarthritis

In vivo

Local

Injection

Engineered

miR-140-5p-overexpressing in human synovial MSCs for the production of enriched EV

[4]